Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Oral herpes

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    104 result(s) found for: Oral herpes. Displaying page 1 of 6.
    1  2  3  4  5  6  Next»
    EudraCT Number: 2006-004015-21 Sponsor Protocol Number: CA-P-3978-01 Start Date*: 2006-08-31
    Sponsor Name:Johnson & Johnson Consumer and Personal Products Worldwide
    Full Title: Randomized Clinical Study Comparing Compeed Cold Sore Patch to Zovirax Cream 5% in the Treatment of Herpes Labialis
    Medical condition: Herpes Labialis
    Disease: Version SOC Term Classification Code Term Level
    8.1 10019942 Herpes labialis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2006-004698-86 Sponsor Protocol Number: AcuZoster Effectiveness2006 Start Date*: 2008-07-16
    Sponsor Name:Schmerzambulanz Innenstadt der LMU
    Full Title: Untersuchung der analgetischen Wirkung der AKupunktur bei Patienten mit Herpes zoster im Vergleich mit einer medikamentösen Standardtherapie- Comparison of acupuncture treatment to medical standard...
    Medical condition: Patients suffering from pain due to a herpes zoster infection
    Disease: Version SOC Term Classification Code Term Level
    8.1 10019974 Herpes zoster LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-000343-10 Sponsor Protocol Number: V211-020-00 Start Date*: 2007-11-20
    Sponsor Name:Merck & Co., Inc.
    Full Title: A Phase IV Clinical Trial to Evaluate the Safety and Tolerability of ZOSTAVAX™ in Subjects ≥60 Years of Age
    Medical condition: Herpes Zoster
    Disease: Version SOC Term Classification Code Term Level
    9.1 10019974 Herpes zoster LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2006-005010-12 Sponsor Protocol Number: CFAM810B2301 Start Date*: 2007-04-02
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A multicenter, open-label, single-arm study to evaluate the single-dose pharmacokinetics, acceptability and safety of famciclovir oral pediatric formulation in infants 1 month to <1 year of age wit...
    Medical condition: herpes simplex or varicella zoster virus infections in infants 1 month to <1 year of age
    Disease: Version SOC Term Classification Code Term Level
    8.1 10019948 Herpes simplex LLT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2007-004020-20 Sponsor Protocol Number: V211-022 Start Date*: 2007-12-10
    Sponsor Name:Merck & Co., Inc.
    Full Title: A Phase III Clinical Trial to Evaluate the Efficacy, Immunogenicity, Safety and Tolerability of ZOSTAVAX™ in Subjects 50 to 59 Years of Age
    Medical condition: Herpes Zoster
    Disease: Version SOC Term Classification Code Term Level
    9.1 10019974 Herpes zoster LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) FI (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2019-000880-26 Sponsor Protocol Number: HTX101-02G Start Date*: 2019-09-03
    Sponsor Name:Heidelberg ImmunoTherapeutics GmbH
    Full Title: A Randomized, Double-Blind, Double-Dummy Phase II Study of Single Dose HDIT101 versus Standard of Care Valaciclovir in Patients with Chronic Recurrent Anogenital HSV-2 Infection
    Medical condition: Chronic recurrent anogenital HSV-2 infection
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10019938 Herpes genitalis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2008-005835-14 Sponsor Protocol Number: Acyclovir01/08 Start Date*: 2008-11-26
    Sponsor Name:MIPHARM
    Full Title: Efficacy and tolerability of a new topical formulation of Acyclovir gel (Acyclorir Liquipatch) given 3 times/day in the treatment of herpes simplex labialis. An open-label, blind controlled, random...
    Medical condition: Herpes Simplex Labialis on the perioral area
    Disease: Version SOC Term Classification Code Term Level
    9.1 10019948 Herpes simplex LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2010-021144-17 Sponsor Protocol Number: EA10-01-998 Start Date*: 2011-01-12
    Sponsor Name:Engelhard Arzneimittel GmbH & Co. KG
    Full Title: A phase III, multi-center, double-blind, randomized, vehicle controlled trial in a parallel-group design to evaluate the efficacy and safety of two formulations of Muxan containing 0.5 % or 1 % chl...
    Medical condition: Male or female patients, aged 12 years or older (first part of the trial: only patients aged 18 years or older), with an adequate history of recurrent herpes labialis and an acute episode of herpes...
    Disease: Version SOC Term Classification Code Term Level
    12.1 10019942 Herpes labialis LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2006-003651-20 Sponsor Protocol Number: V211-017 Start Date*: 2007-06-04
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase III Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of Zoster Vaccine Live (Oka/Merck) in Patients on Chronic/Maintenance Corticosteroids
    Medical condition: Zoster Vaccine
    Disease: Version SOC Term Classification Code Term Level
    8.1 10019974 Herpes zoster LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) BE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-004316-31 Sponsor Protocol Number: FPP4-DE-401 Start Date*: 2009-02-23
    Sponsor Name:Novartis Consumer Health S.A.
    Full Title: A randomised, double-blind, vehicle controlled, single centre, parallel group, comparative study of the efficacy of penciclovir 10 mg/g (1%) cream in preventing the appearance of classical lesions ...
    Medical condition: Cold Sores caused by the herpes simplex virus (HSV) type 1.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10049352 Cold sores lip LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2020-000926-24 Sponsor Protocol Number: HTX101-03L Start Date*: 2020-08-17
    Sponsor Name:Heidelberg ImmunoTherapeutics
    Full Title: A Randomised, Double-Blind Phase II Trial of Topical HDIT101 versus Placebo in Patients with Chronic Recurrent HSV-1 Infection and Orolabial Lesion
    Medical condition: Chronic Herpes Simplex Virus-1 Infection
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004862 10073933 Herpes simplex oral LLT
    22.0 100000004862 10082141 Herpes simplex labialis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-002313-11 Sponsor Protocol Number: V212-009-00 Start Date*: 2012-01-20
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase II Randomized, Placebo-Controlled Clinical Trial to Study the Safety and Immunogenicity of V212 in Adult Patients with Autoimmune Disease
    Medical condition: Prevention of herpes zoster in adults with autoimmune disease
    Disease: Version SOC Term Classification Code Term Level
    15.0 10021881 - Infections and infestations 10019974 Herpes zoster PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) BE (Completed) EE (Completed) DK (Completed) ES (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2007-000344-26 Sponsor Protocol Number: V211-012-00 Start Date*: 2007-06-04
    Sponsor Name:Merck & Co., Inc.
    Full Title: A Phase III Double-Blind, Randomized Multicenter Study to Evaluate the Safety, Tolerability and Immunogenicity of ZOSTAVAX administered comcomitantly versus Non-concomitantly with PNEUMOVAX 23 in s...
    Medical condition: herpes zoster, pneumococcal infection
    Disease: Version SOC Term Classification Code Term Level
    9.1 10019974 Herpes zoster LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed) GB (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2009-012458-19 Sponsor Protocol Number: ZTV03C Start Date*: 2009-10-15
    Sponsor Name:Sanofi Pasteur MSD S.N.C.
    Full Title: An open-label, randomised, comparative, multicentre study of the immunogenicity and safety of ZOSTAVAX® when administered by intramuscular route or subcutaneous route to subjects ≥50 years of age
    Medical condition: Not applicable as Prevention of herpes zoster ("zoster" or shingles) and herpes zoster-related post-herpetic neuralgia (PHN).
    Disease: Version SOC Term Classification Code Term Level
    12.0 10019974 Herpes zoster LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2018-002387-86 Sponsor Protocol Number: 218S18VC Start Date*: 2020-01-08
    Sponsor Name:Pascoe pharmazeutische Präparate GmbH
    Full Title: A DOUBLE-BLIND, PLACEBO-CONTROLLED, 4-ARM PILOT STUDY ON THE USE OF PASCORBIN® AS ADD-ON THERAPY IN PATIENTS WITH ACUTE HERPES ZOSTER
    Medical condition: Acute herpes zoster infection
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10019974 Herpes zoster PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2005-003035-52 Sponsor Protocol Number: V211-011-00 Start Date*: 2005-10-06
    Sponsor Name:Merck & Co. Inc.
    Full Title: A Double-Blind, Randomized, Multicenter Study to Evaluate the Safety, Tolerability, and Immunogenicity of ZOSTAVAX™ Administered Concomitantly Versus Nonconcomitantly with Influenza Virus Vaccine (...
    Medical condition: Herpes Zoster
    Disease: Version SOC Term Classification Code Term Level
    8.0 10019974 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-001451-30 Sponsor Protocol Number: UMCN-AKF12.07 Start Date*: 2019-06-17
    Sponsor Name:Radboud university medical center
    Full Title: Pharmacokinetics of a new paediatric formulation of valacyclovir used for prophylaxis and treatment of VZV and HSV infections in children, phase II (VALID II)
    Medical condition: Herpes virus infections, especially Herpes Simplex and Varicella Zoster.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10019973 Herpes virus infection PT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-001778-17 Sponsor Protocol Number: 201190 Start Date*: 2016-03-17
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase IIIb, open-label, multi-country, multi-centre, long-term follow-up study (ZOE-LTFU) of studies 110390 and 113077 (ZOSTER-006/022) to assess the prophylactic efficacy, safety, and immunogeni...
    Medical condition: Vaccination against HZ and its related complications in adults older than 50 years (at the time of primary vaccination).
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004862 10019982 Herpes zoster NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) EE (Completed) CZ (Completed) GB (GB - no longer in EU/EEA) DE (Completed) ES (Ongoing) IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-000577-22 Sponsor Protocol Number: AKF-UMCN11.05 Start Date*: 2012-07-17
    Sponsor Name:Radboud University Nijmegen Medical Centre
    Full Title: Palatability testing of a new paediatric formulation of valacyclovir for the prophylaxis and treatment of VZV and HSV infections in children – VALID 0
    Medical condition: Herpes virus infections, especially Herpes Simplex, Varicella Zoster and Cytomegalovirus
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10019973 Herpes virus infection PT
    Population Age: Children, Under 18, Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2019-001085-15 Sponsor Protocol Number: LLB-2018-01 Start Date*: 2019-11-06
    Sponsor Name:LABO’LIFE Belgium sprl
    Full Title: Randomized, placebo-controlled, double-blind study to evaluate the efficacy of 2LHERP® in patients with recurrent orofacial herpes infections.
    Medical condition: Patients presenting recurrent orofacial herpes infections (6 or more episodes within the 12-months’ period prior to their study entry).
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10019972 Herpes viral infections HLT
    20.1 10021881 - Infections and infestations 10067152 Oral herpes PT
    21.1 10021881 - Infections and infestations 10019948 Herpes simplex PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 13 10:20:00 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA